An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: An immunoproteomics investigation

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1097-1104

  Hamrita, Bechr ^a   Nasr, Hela Ben ^a   Hammann, Philippe ^b   Kuhn, Lauriane ^b   Guillier, Christelle Lemaitre ^c   Chaieb, Anouar ^a,d   Khairi, Hedi ^a,d   Chahed, Karim ^a,e  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b CNRS   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d FARHAT HACHED HOSPITAL   (Tunisia)

^e UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Autoantibody; Elongation factor Tu; Immunoproteomics; Infiltrating ductal breast carcinomas; SERPA

Indexed keywords

AUTOANTIBODY; CYTOKERATIN 8; ELONGATION FACTOR; ELONGATION FACTOR LIKE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOPROTEOMICS; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; TUMOR IMMUNITY; TUMOR VOLUME;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; PEPTIDE ELONGATION FACTOR TU; PROTEOMICS; SEROLOGIC TESTS;

EID: 80051691489     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.005     Document Type: Article

References (36)

1. Hill C., Doyon F. Frequency of cancer in France. Bull Cancer 2004, 91:9-14.
2. Brooks M. Breast cancer screening and biomarkers. Methods Mol Biol 2009, 472:307-321.
3. Nicolini A., Carpi A., Tarro G. Biomolecular markers of breast cancer. Front Biosci 2006, 11:1818-1843.
4. Hondermarck H., Vercoutter-Edouart A.S., Révillion F., Lemoine J., el-Yazidi-Belkoura I., Nurcombe V. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 2001, 1:1216-1232.
5. Brichory F., Beer D., Le Naour F., Giordano T., Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001, 61:7908-7912.
6. Piura E., Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol Nov. 21 2010, 10.1155/2010/264926.
7. Piura E., Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol Mar. 3 2011, 10.1155/2011/982425.
8. Piura B., Piura E. Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol Jan. 17 2009, 10.1155/2009/581939.
9. Yang F., Xiao Z.Q., Zhang X.Z. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007, 6:751-758.
10. Raedle J., Oremek G., Truschnowitsch M., Lorenz M., Roth W.K., Caspary W.F., et al. Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer 1998, 34:1198-1203.
11. Covini G., Chan E.K., Nishioka M., Morshed S.A., Reed S.I., Tan E.M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997, 25:75-80.
12. Stenner-Liewen F., Luo G., Sahin U., Tureci O., Koslovski M., Kautz I., et al. Definition of tumor-associated antigens in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2000, 9:285-290.
13. Takashima M., Kuramitsu Y., Yokoyama Y. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 2006, 6:3894-3900.
14. Fujita Y., Nakanishi T., Hiramatsu M. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:6415-6420.
15. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
16. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., Scholl S. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7:3328-3335.
17. Gao R.J., Bao H.Z., Yang Q., Cong Q., Song J.N., Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat 2005, 93:111-115.
18. Fischer E., Kobold S., Kleber S., Kubuschok B., Braziulis E., Knuth A., et al. Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol 2010, 185:3095-3102.
19. Isla Larrain M., Demichelis S., Crespo M., Lacunza E., Barbera A., Cretón A., et al. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1). J Exp Clin Cancer Res 2009, 28:121.
20. Conroy S.E., Sasieni P.D., Amin V., Wang D.Y., Smith P., Fentiman I.S., et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer 1998, 77:1875-1879.
21. Bachelot T., Ratel D., Menetrier-Caux C., Wion D., Blay J.Y., Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 2006, 94:1066-1070.
22. Kanojia D., Garg M., Gupta S., Gupta A., Suri A. Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:630-639.
23. Erić A., Juranić Z., Milovanović Z., Marković I., Inić M., Stanojević-Bakić N., et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 2009, 15:89-90.
24. Desmetz C., Bascoul-Mollevi C., Rochaix P., Lamy P.J., Kramar A., Rouanet P., et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009, 15:4733-4741.
25. Chahed K., Kabbage M., Ehret-Sabatier L., Lemaitre-Guillier C., Remadi S., Hoebeke J., et al. Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast, the two-dimensional electrophoresis and MALDITOF- mass spectrometry analyses. Int J Oncol 2005, 27:1425-1431.
26. Kothe U., Wieden H.-J., Mohr D., Rodnina M.V. Interaction of helix D of elongation factor Tu with helices 4 and 5 of protein L7/12 on the ribosome. J Mol Biol 2004, 336:1011-1021.
27. Yang W., Boss W.F. Regulation of phosphatidylinositol 4-kinase by the protein activator PIK-A49, activation requires phosphorylation of PIK-A49. J Biol Chem 1994, 269:3852-3857.
28. Forgber M., Trefzer U., Sterry W., Walden P. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009, 4:5199-5205.
29. Thornton S., Anand N., Purcell D., Lee J. Not just for housekeeping, protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003, 81:536-548.
30. Talapatra S., Wagner J.D., Thompson C.B. Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ 2001, 9:856-861.
31. Johnsson A., Zeelenberg I., Min Y., Hilinski J., Berry C., Howell S.B., et al. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 2000, 83:1047-1054.
32. Levine J.S., Koh J.S. The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant. Semin Nephrol 1999, 19:34-47.
33. Alexander C., Bilgin N., Lindschau C., Mesters J.R., Kraal B., Hilgenfeld R., et al. Phosphorylation of elongation factor Tu prevents ternary complex formation. J Biol Chem 1995, 270:14541-14547.
34. Granato D., Bergonzelli G.E., Pridmore R.D., Marvin L., Rouvet M., Corthésy-Theulaz I.E. Cell surface-associated elongation factor Tu mediates the attachment of Lactobacillus johnsonii NCC533 (La1) to human intestinal cells and mucins. Infect Immun 2004, 72:2160-2169.
35. De Moreno de LeBlanc A., Matar C., LeBlanc N., Perdigón G. Effects of milk fermented by Lactobacillus helveticus R389 on a murine breast cancer model. Breast Cancer Res 2005, 7:477-493.
36. Matar C., LeBlanc J.G., Martin L., Perdigón G. Biologically active peptides released in fermented milk: role and functions. Handbook of fermented functional foods 2003, 177.